Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Veracyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VCYT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VCYT exceeded the US Biotechs industry which returned 39.7% over the past year.
Return vs Market: VCYT exceeded the US Market which returned 17.2% over the past year.
Price Volatility Vs. Market
How volatile is Veracyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
18 hours ago | Simply Wall StIntroducing Veracyte (NASDAQ:VCYT), The Stock That Soared 420% In The Last Five Years
1 month ago | Simply Wall StHave Insiders Been Selling Veracyte, Inc. (NASDAQ:VCYT) Shares?
2 months ago | Simply Wall StHere's What We Think About Veracyte's (NASDAQ:VCYT) CEO Pay
Is Veracyte undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VCYT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VCYT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VCYT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: VCYT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VCYT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VCYT is overvalued based on its PB Ratio (7.2x) compared to the US Biotechs industry average (3.4x).
How is Veracyte forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VCYT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VCYT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VCYT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VCYT's revenue (21.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: VCYT's revenue (21.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VCYT is forecast to be unprofitable in 3 years.
How has Veracyte performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VCYT is currently unprofitable.
Growing Profit Margin: VCYT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VCYT is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare VCYT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VCYT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: VCYT has a negative Return on Equity (-13.68%), as it is currently unprofitable.
How is Veracyte's financial position?
Financial Position Analysis
Short Term Liabilities: VCYT's short term assets ($172.7M) exceed its short term liabilities ($13.1M).
Long Term Liabilities: VCYT's short term assets ($172.7M) exceed its long term liabilities ($17.5M).
Debt to Equity History and Analysis
Debt Level: VCYT's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: VCYT's debt to equity ratio has reduced from 7.7% to 0.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VCYT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VCYT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 17.5% each year
What is Veracyte current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VCYT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VCYT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VCYT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VCYT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VCYT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bonnie Anderson (62 yo)
Ms. Bonnie H. Anderson co-founded Veracyte, Inc. in 2008 and has served as its Chief Executive Officer and a Member of Board of Directors since February 2008. Ms. Anderson is Chairman of the Board at Verac ...
CEO Compensation Analysis
Compensation vs Market: Bonnie's total compensation ($USD4.16M) is about average for companies of similar size in the US market ($USD4.57M).
Compensation vs Earnings: Bonnie's compensation has increased whilst the company is unprofitable.
|CFO & COO||3.75yrs||US$2.77m||0.10% |
|Chief Scientific & Medical Officer||12yrs||US$2.12m||0.0019% |
|Chief Commercial Officer||3.58yrs||US$2.03m||0.039% |
|Principal Accounting Officer||1.17yrs||no data||0.033% |
|Chief Information Officer||3.5yrs||no data||no data|
|Vice President of Corporate Communications & Investor Relations||0.42yr||no data||no data|
|Executive VP||0.17yr||no data||no data|
|Vice President of Marketing||2.67yrs||no data||no data|
|Vice President of Corporate & Business Development||1.42yrs||no data||no data|
|Senior Medical Director of Endocrinology||8.42yrs||no data||no data|
|Assistant Controller||4.92yrs||no data||no data|
Experienced Management: VCYT's management team is considered experienced (3.5 years average tenure).
|Independent Director||7.75yrs||US$196.04k||0.023% |
|Independent Director||13.67yrs||US$185.04k||0% |
|Independent Director||12.58yrs||US$185.04k||0.044% |
|Lead Independent Director||3.75yrs||US$209.04k||0% |
|Independent Director||4.83yrs||US$186.80k||0% |
|Independent Director||3.75yrs||US$194.04k||0% |
|Independent Director||5.67yrs||US$189.04k||0% |
|Director||0.17yr||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Clinical Advisory Board||no data||no data||no data|
|Member of Clinical Advisory Board||no data||no data||no data|
Experienced Board: VCYT's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.8%.
Veracyte, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Veracyte, Inc.
- Ticker: VCYT
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.838b
- Shares outstanding: 56.58m
- Website: https://www.veracyte.com
Number of Employees
- Veracyte, Inc.
- 6000 Shoreline Court
- Suite 300
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VCYT||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Oct 2013|
|12V||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2013|
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify pa ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/01 00:41|
|End of Day Share Price||2020/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.